. Author manuscript; available in PMC: 2017 Sep 1.

Published in final edited form as: Eur J Cancer. 2016 Jul 14;64:149–158. doi: 10.1016/j.ejca.2016.05.028

Table 3.

Multivariate Cox's regression analysis of disease-free survival in endometrial cancer patients of the validation series including standard clinicopathologic parameters and MSH6 protein expression assessed by immunohistochemical analysis.

All endometrial cancers validation series (n=243)
	HR (95% CI)	P
Age	2.552 (1.359-4.793)	0.004
Grade	1.834 (1.225-2.747)	0.003
Histology	1.092 (0.445-2.680)	0.848
FIGO stage	2.025 (1.387-2.956)	<0.001
MSH6 protein expression (high vs low)	2.150 (1.104-4.190)	0.024

Statistically significant P-values are highlighted in bold. CI, confidence interval; HR, hazard ratio.